Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of 5 azole antifungals and 1 active metabolite

Azole antifungal medications are often administered to prevent or treat invasive fungal infections. These infections are deadly in the immunocompromised population. Therapeutic drug monitoring of the azole antifungal medications may potentially decrease morbidity and mortality in patients undergoing...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2017-11, Vol.474, p.8-13
Main Authors: McShane, Adam J., Wang, Sihe
Format: Article
Language:English
Subjects:
Antifungal
Antifungal Agents - blood
Antifungal Agents - metabolism
Azole
Azoles - blood
Azoles - metabolism
Blood Chemical Analysis - methods
Chromatography, Liquid - methods
Humans
Invasive fungal infection
Liquid chromatography
Mass spectrometry
Tandem Mass Spectrometry - methods
Therapeutic drug monitoring
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Azole antifungal medications are often administered to prevent or treat invasive fungal infections. These infections are deadly in the immunocompromised population. Therapeutic drug monitoring of the azole antifungal medications may potentially decrease morbidity and mortality in patients undergoing azole treatment. To assist with azole therapeutic drug monitoring, a liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for 6 azole analytes: fluconazole, voriconazole, posaconazole, isavuconazole, itraconazole, and its active metabolite hydroxyitraconazole. The validated method solely required a protein precipitation step before subsequent dilution and injection onto the LC-MS/MS system. Furthermore, the analysis time was
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2017.08.032